Commerzbank Aktiengesellschaft FI Has $1.84 Million Stake in Danaher Co. (NYSE:DHR)

Commerzbank Aktiengesellschaft FI lifted its holdings in Danaher Co. (NYSE:DHR) by 80.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,632 shares of the conglomerate’s stock after purchasing an additional 2,952 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Danaher were worth $1,844,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Tsfg LLC raised its holdings in Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares in the last quarter. nVerses Capital LLC bought a new position in Danaher during the second quarter worth about $25,000. CarsonAllaria Wealth Management Ltd. acquired a new stake in Danaher in the 2nd quarter worth about $25,000. Redmont Wealth Advisors LLC bought a new stake in Danaher in the 1st quarter valued at about $30,000. Finally, MFA Wealth Advisors LLC acquired a new position in shares of Danaher during the 2nd quarter worth approximately $51,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

DHR has been the subject of several recent research reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 price target on shares of Danaher in a research note on Friday, September 6th. Stephens assumed coverage on Danaher in a report on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 target price on the stock. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Evercore ISI boosted their target price on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Finally, Wells Fargo & Company assumed coverage on shares of Danaher in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price target on the stock. Seven research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $282.65.

Danaher Stock Performance

NYSE:DHR opened at $256.29 on Wednesday. The company has a market capitalization of $189.83 billion, a PE ratio of 43.99, a P/E/G ratio of 4.49 and a beta of 0.83. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The company has a 50 day simple moving average of $270.67 and a two-hundred day simple moving average of $260.46.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter last year, the firm earned $2.02 earnings per share. Danaher’s quarterly revenue was up 3.1% on a year-over-year basis. Research analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be paid a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.42%. Danaher’s dividend payout ratio is currently 18.31%.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is owned by corporate insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.